Reporting from the ASCO Genitourinary Symposium 2022, Petros Grivas comments on data from studies that support further evaluation in urothelial cancer, in particular sacituzumab govitecan + pembrolizumab in the metastatic setting for platinum-refractory disease, nivolumab + trastuzumab deruxtecan in patients with HER2-expressing tumour, and single agent enfortumab vedotin in the neoadjuvant setting before radical cystectomy in patients who are cisplatin-ineligible.
Abstracts:
- 434 - TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens.
- 438 - Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).
- 435 - Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible.